Friday, 16 October 2026European Markets

TGS Stock Bullish Momentum With A 11.06% Rise On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with TGS (TGS.OL) jumping 11.06% to kr132.50 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.13% to kr1,352.65.

TGS's last close was kr119.30, 40.59% below its 52-week high of kr200.80.

About TGS

TGS ASA provides geoscience data services to the oil and gas industry worldwide. The company offers geophysical data, including multi-client seismic data; geological data comprising well data products, and interpretive studies and services; and interpretation products and data integration solutions. It also provides imaging services, which include 2D and 3D seismic imaging solution in depth and time domains; marine, land, and ocean bottom nodes; and transition zone, multi component, and 4D time-lapse processing. The company was formerly known as TGS-NOPEC Geophysical Company ASA and changed its name to TGS ASA in June 2021. TGS ASA was founded in 1981 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, TGS has a trailing twelve months EPS of kr6.44.

PE Ratio

TGS has a trailing twelve months price to earnings ratio of 20.57. Meaning, the purchaser of the share is investing kr20.57 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.72%.

Growth Estimates Quarters

The company's growth estimates for the present quarter and the next is 275% and 39.5%, respectively.

Volume

Today's last reported volume for TGS is 1960090 which is 214.34% above its average volume of 623555.

More news about TGS (TGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com